BU
EW icon

BBVA USA’s Edwards Lifesciences EW Stock Holding History

BBVA USA’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$307K Sell
2,712
-1,518
-36% -$173K 0.02% 392
2021
Q2 		$438K Buy
+4,230
New +$399K 0.02% 367

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBVA USA's EW Position: Q3 2021 in Review

BBVA USA reduced its Edwards Lifesciences (EW) stake by 36% in Q3 2021, selling an estimated $173K and leaving 2,712 shares worth $307K. The position accounts for 0.02% of the portfolio, ranked #392.

BBVA USA first reported a position in EW in Q2 2021 and has held it in 2 quarters since. The position peaked at $438K in Q2 2021. 1,227 funds tracked by Wall St. Rank hold EW as of Q3 2021.

  • BBVA USA held 2,712 shares of Edwards Lifesciences worth $307K as of Q3 2021.
  • BBVA USA sold 1,518 Edwards Lifesciences shares in Q3 2021, an estimated $173K.
  • Edwards Lifesciences made up 0.02% of BBVA USA's portfolio in Q3 2021, its #392 holding.
  • BBVA USA first reported a position in Edwards Lifesciences in Q2 2021 and has held it in 2 quarters since.
  • BBVA USA's Edwards Lifesciences position peaked at $438K in Q2 2021.
  • 1,227 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.